ArticleFrontiers in immunology2026
Efficacy and safety of sequential immunotherapy following concurrent radiotherapy with S-1 in older patients with esophageal squamous cell carcinoma: an inverse probability weighting analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the efficacy and safety of sequential immune checkpoint inhibitors (ICIs) following concurrent chemoradiotherapy (CCRT) in older (≥70 years) patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods: A total of 193 older patients (≥70 years) with locally advanced ESCC treated between January 2022 and December 2023 were retrospectively analyzed and divided into two groups: the CCRT group (radiotherapy with concurrent S-1, n=108) and the CCRT+ICIs group (sequential ICIs after CCRT, n=85). Baseline imbalances were adjusted via inverse probability of treatment weighting (IPTW). The primary endpoints were overall survival (OS) and progression-free survival (PFS), whereas the secondary endpoints included safety and prognostic factors. Results: After IPTW adjustment, OS in the CCRT+ICIs group tended to improve compared with that in the CCRT alone group (HR = 0.70, 95% CI: 0.48-1.04, p=0.071), although the difference was not statistically significant. In contrast, PFS was significantly improved in the CCRT+ICIs group (HR = 0.59, 95% CI: 0.42-0.84, p=0.003). Multivariate analysis identified age ≥75 years (OS: HR = 1.893; PFS: HR = 2.097), ECOG score =2 (OS: HR = 3.310; PFS: HR = 2.188), T4 stage (OS: HR = 2.221; PFS: HR = 2.080), and N3 stage (OS: HR = 3.841; PFS: HR = 2.920) as independent adverse prognostic factors. Immunotherapy-specific toxicities, including hypothyroidism and pneumonitis, occurred more frequently in the CCRT+ICIs group, which is consistent with the toxicity profile of ICIs, whereas neutropenia and vomiting were less common. A lower incidence of vomiting was also observed in the CCRT+ICIs group, although the difference did not reach statistical significance (p=0.053). Conclusion: Sequential ICI therapy after CCRT significantly improved PFS and reduced mortality risk in older ESCC patients, though close monitoring is warranted for pneumonitis and skin-related toxicities. The reduced incidence of neutropenia suggests a hematologic safety advantage of the sequential strategy. Patients aged ≥75 years, with an Eastern Cooperative Oncology Group (ECOG) score of 2, or with N3 disease constitute high-risk subgroups and warrant individualized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.